Progress in immunotherapy of cancer

New England Journal of Medicine

Volumn 367, Issue 12, 2012, Pages 1168-

  Rook, Alain H ^a   Raphael, Brian A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LETTER; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUVA; SEZARY SYNDROME;

EID: 84866426350     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1208946     Document Type: Letter

References (4)

1. Topalian SL, Hodi S, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
2. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
3. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-9.
4. Raphael BA, Shin DB, Suchin KR, et al. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol 2011;147:1410-5.